Results 251 to 260 of about 118,937 (337)
Abstract Objectives The objective of this study was to compare the efficacy of oral and intralesional steroid injection in the treatment of idiopathic granulomatous mastitis (IGM) cases with clinical, ultrasonography (US) and Superb microvascular imaging (SMI) findings.
Oğuz Karakayalı+6 more
wiley +1 more source
Syndecan-1 as a predictor of vulnerable atherosclerotic plaques. [PDF]
Qiu Y+5 more
europepmc +1 more source
Gelatinase and Vulnerability of Atherosclerotic Plaque
openaire +4 more sources
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post+4 more
wiley +1 more source
Contribution of multimodal ultrasound in evaluating the efficacy of lumbricus protein fast dissolving tablets against atherosclerotic plaques in ApoE<sup>(-/-)</sup> mice. [PDF]
Lu Z+8 more
europepmc +1 more source
Sphingolipids are vital components of cell membranes. Metabolic disruptions of sphingolipids, including ceramide and sphingosine‐1‐phosphate, are linked to neurological disorders. This article summarizes the classification, structure, and metabolic processes of sphingolipids, and the physiological and pathological effects of sphingolipid metabolism and
Tian Li+7 more
wiley +1 more source
Apolipoprotein A1 deficiency increases macrophage apoptosis and necrotic core development in atherosclerotic plaques in a Bim-dependent manner. [PDF]
Qian AS+5 more
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source